Skip to content
10-Q

Quarterly Report

Audentes Therapeutics, Inc.

0001628280-19-006182

← back to feed
Filed
May 8, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · May 3, 2019 44.29M sh
Capex Q1 2019 · Mar 31, 2019 $1.29M
Capex Q1 2019 · Mar 31, 2018 $921K
Operating Cash Flow Q1 2019 · Mar 31, 2019 −$42.22M
Operating Cash Flow Q1 2019 · Mar 31, 2018 −$24.59M
Short Term Investments Q1 2019 · Mar 31, 2019 $236.34M
Short Term Investments Q1 2019 · Dec 31, 2018 $269.96M
Cash And Equivalents Q1 2019 · Mar 31, 2019 $133.16M
Cash And Equivalents Q1 2019 · Dec 31, 2018 $144.35M
Stockholders Equity Q1 2019 · Mar 31, 2019 $402M
Stockholders Equity Q1 2019 · Dec 31, 2018 $442.75M
Current Liabilities Q1 2019 · Mar 31, 2019 $26.1M
Current Liabilities Q1 2019 · Dec 31, 2018 $23.85M
Total Liabilities Q1 2019 · Mar 31, 2019 $53.18M
Total Liabilities Q1 2019 · Dec 31, 2018 $29.8M
Current Assets Q1 2019 · Mar 31, 2019 $373.16M
Current Assets Q1 2019 · Dec 31, 2018 $419.77M
Total Assets Q1 2019 · Mar 31, 2019 $455.18M
Total Assets Q1 2019 · Dec 31, 2018 $472.56M
Sga Expense Q1 2019 · Mar 31, 2019 $11.99M
Sga Expense Q1 2019 · Mar 31, 2018 $6.52M
Rd Expense Q1 2019 · Mar 31, 2019 $39.84M
Rd Expense Q1 2019 · Mar 31, 2018 $19.89M
Net Income Q1 2019 · Mar 31, 2019 −$49.39M
Net Income Q1 2019 · Mar 31, 2018 −$25.57M
Operating Income Q1 2019 · Mar 31, 2019 −$51.83M
Operating Income Q1 2019 · Mar 31, 2018 −$26.41M